OHMX.bio is an enthusiastic young company, which helps customers solve their biological questions through cutting-edge technologies over different OMICS fields.
One of the flagships in its technology portfolio is translation profiling. In molecular biology, translation describes the process in which novel proteins are synthetized from the available mRNA. This process is conducted by a molecular complex, called the ribosome, and it takes place in all cells of all organisms. Translation profiling (or RIBO-seq) is a recent analysis technique that measures the sequence information that is being translated. In this analysis, the small fragments of translated mRNA, which are protected inside the ribosomal complexes, are read using next-generation sequencing technology. In this way, RIBO-seq provides a genome-wide quantitative snapshot of the full translatome (translatomics). RIBO-seq can be positioned in between traditional RNA-seq (transcriptomics) and mass spectrometry-based proteomics, as it combines the advantages of deep sequencing with measurements on the level of protein synthesis. At OHMX.bio, the RIBO-seq workflow is routinely performed starting from different sorts of input material, ranging from cell cultures over tissue samples to organoids. Translation profiling can provide very interesting information for many applications. For example, the impact of mRNA, gene or cell therapy on translation can be assessed. Furthermore, it can aid in studying the influence of external factors, induced stress and different compounds on the genome-wide protein synthesis patterns. In brief, unraveling the mode of action (MoA) at the functional level is made possible. In all of these use cases, differential translation can be checked for known genes but in the same dataset, also alternative translation products and novel translation events are possibly discovered. On top of that, OHMX.bio frequently combines translatomic results with data from other OMICS technologies, to provide a multi-OMIC research insight.